血液灌流治疗尿毒症难治性高血压的临床观察

The Observation of Clinical Efficacy of Hemoperfusion in the Uremic Patients with Refractory Hypertension

目的 观察血液灌流（HP）联合血液透析（HD）应用于维持性HD患者合并难治性高血压的降压疗效.方法 将46例维持性HD伴难治性高血压的患者随机分为HD组和HP组,HD组进行每周3次常规透析,HP组在常规透析基础上每两周接受一次HD＋HP治疗,两组同时根据血压调整降压药用量,治疗时间为12周.比较两组患者治疗前后血压及使用降压药种类情况,再根据平均动脉压比较两组的血压下降幅度.结果 两组血压均有下降,HP组血压下降更为明显,同时HP组使用降压药种类较HD组少.结论 对于维持性HD合并难治性高血压患者,HP有显著的降压作用.

Objective To observe the clinical efficacy of hemoperfusion combined with hemodialysis in hemodialysis patients with refractory hypertension. Methods 46 patients with hemodialysis and refractory hypertension were randomly divided into the hemodialysis group and the hemoperfusion group,three times hemodialysis a week in hemodialysis group,every two weeks,one time hemoperfusion was added in the hemoperfusion group,the amount of antihypertensive drug were adjusted according to blood pressure in two groups while the 12 weeks treatment time.Blood pressure and the types of drugs were compared before and after treatment.And then according to mean arterial blood pressure the level of decrease was compared between the two groups. Results The blood pressures in both groups were decreased.The blood pressure decreased more significantly in the hemoperfusion group,while the hemoperfusion group used fewer types of antihypertensive drugs. Conclusion The hemoperfusion has a significant effect in the patients with hemodialysis and refractory hypertension.